close

Login

Library
Shopping Cart
Remember Me
Forgot password/Login issues?
loading animation for AJAX calls
 
 
Direct (781) 489-7301,  Toll Free (866) 285-7215

Search

Search
BCC Advance Search

Choose your License

loading animation for AJAX calls

Global Markets for Drug-Device Combinations

REPORT HIGHLIGHTS

This report provides:

  • An overview of the global market for drug-device combinations
  • Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017
  • Detailed coverage of such product categories as drug-eluting stents (DES), drug-eluting beads (DEB), antimicrobial catheters, antibiotic-loaded bone cements, glass ionomer cements, bone graft substitutes, antibacterial-releasing dental-restorative materials, biologic wound-care products such as collagen-based dressings as therapeutic agents for wound-healing, drug-device combination products for ocular applications, and photodynamic therapy
  • Identification of current and future technologies, products, market segments/end markets, and government and regulatory agencies
  • Discussion of participating companies in light of technological strengths and weaknesses, relative market shares, marketing strengths, and innovative marketing practices
  • Detailed patent analysis and research and development updates
  • Comprehensive company profiles of major players.

SAMPLE FIGURE
SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2011-2017
($ BILLIONS)
SALES OF DRUG DEVICE COMBINATION PRODUCTS, 2011-2017
To Contact us, click here  help


Source: BCC Research

REPORT SCOPE

INTRODUCTION

STUDY GOALS AND OBJECTIVES

This report analyzes the market for drug-device combination products.  It provides descriptions of technologies and products, a review of the status of research and development (R&D) initiatives and a forecast of market revenues through 2017.  Company profiles, clinical trials, and a patent analysis are provided as well.  Example product categories that are covered include:

  • Drug-eluting stents (DES).
  • Drug-eluting beads (DEB).
  • Transdermal patches.
  • Antimicrobial catheters.
  • Antibiotic-loaded bone cements.
  • Glass ionomer cements.
  • Bone graft substitutes.
  • Antibacterial-releasing dental restorative materials.
  • Biologic wound care products, such as collagen-based dressings as therapeutic agents for wound healing.
  • Drug-device combination products for ocular applications.
  • Photodynamic therapy.

THE IMPORTANCE OF THIS STUDY

Products that combine a drug or biologic with a device, such as drug-eluting stents and drug-delivery systems, can offer valuable approaches for treating diseases.  In addition, developments in cell-based therapeutics, progenitor cell exploitation, growth factor delivery and advanced formulation strategies are becoming the basis of even more advanced combination device strategies.  Technology advancements in the drug-device combination market have been of considerable importance in recent years, and the pace of activity seems to be quickening with the appearance of many development-stage companies.

Since the approval of Johnson & Johnson’s Cypher drug-eluting stent in 2003 and Boston Scientific’s Taxus drug-eluting stent in 2004, drug-device combination products have attracted significant medical and media attention.  But combination products are subject to intense regulatory scrutiny for safety and effectiveness.  Teams of device and drug product reviewers at a number of Food and Drug Administration (FDA) centers are dedicated to evaluating such products.  Thus, the bar is very high for FDA product approvals, and consequently combination products in certain categories are very small in number.  For example, the entire fibrin sealant market is shared by a handful of FDA-approved products such as TachoSil, the first absorbable fibrin sealant patch for use in cardiovascular surgery.  Beyond drug-eluting stents and other categories noted above, combination products subject to FDA scrutiny include innovative drug-delivery systems, hemostatic sealants, photodynamic-therapy systems, gene-therapy systems, and products for many other investigational treatments.

The development of the market for combination products is closely related to another dynamic and fast growing healthcare segment generally termed “drug-delivery systems”.  “Delivery systems” represents a vast area of research, and development within biomaterials and medicine and the demand for sophisticated drug-delivery devices is behind many novel product developments.  Advanced drug-delivery devices offer increased efficiency, improved performance and convenience.

INTENDED AUDIENCE

With its broad scope and in-depth analyses, this study will prove to be a valuable resource, particularly for anyone involved with or interested in the future of the fast-growing drug-device combination market.  This study will be particularly useful for researchers, laboratory and government personnel working in research or company settings, as well as business professionals involved with drug and device development.  It also will be of value to potential investors and members of the general public interested in acquiring a business-oriented view of a key health care sector in the economy.  The projections, forecasts, and trend analyses found in this report provide readers with the necessary data and information for decision-making.

SCOPE AND FORMAT

In preparing this report, an overall study of the drug-device combination market was undertaken.

The report covers the following product categories:

  • Drug-eluting stents (DES).
  • Drug-eluting beads (DEB).
  • Transdermal patches.
  • Antimicrobial catheters.
  • Antibiotic-loaded bone cements.
  • Glass ionomer cements.
  • Bone graft substitutes.
  • Antibacterial-releasing dental restorative materials.
  • Biologic wound care products, such as collagen-based dressings as therapeutic agents for wound healing.
  • Drug-device combination products for ocular applications.
  • Photodynamic therapy.
  • Many nanotechnology applications.

Devices that do not combine a drug with the delivery mechanism are not covered; for example, insulin pumps are not covered.

Related areas, such as drug delivery systems and nanotechnology, were key to the analysis as well, as these newer areas such as nanotechnology foreshadow likely product developments in the years ahead.  All major aspects of the drug-device combination market are addressed including identification of current and future technologies, products, market segments/end markets, and government and regulatory involvement.  Participating companies are discussed in light of technological strengths and weakness, relative market share, marketing strengths, and innovative marketing practices.  Included is a detailed discussion of the current regulatory environment for drug-device combination products and how it is affecting development and approval of such products.

METHODOLOGY AND INFORMATION SOURCES

Data for this study were collected using both primary and secondary data research techniques.  A literature search was conducted covering scientific, medical, business and technical documents, as well as patents.  Since most segments of the drug-device combination market are not routinely measured via an economic census, BCC derived estimates from a variety of sources.  Whenever market estimates are derived, they are fully noted.  All forecasts are in current (nominal) dollars, unadjusted for inflation.

ANALYST CREDENTIALS

Research analyst Kevin Gainer holds both B.A. and M.A. degrees in quantitative economic analysis and forecasting, and has 26 years of economic forecasting, industry intelligence and market research experience.  He is the author of six published books and more than 100 magazine articles, technical papers, analyses, and studies published in conference proceedings, including many unpublished within corporations.  He has worked as a Research Editor and Project Analyst at BCC Research since 1985, and has authored numerous BCC technology market research reports.

BCC ON-LINE SERVICES

BCC Research offers an online information retrieval service.  Its home page, located at www.bccresearch.com, enables readers to:

  • Examine the complete BCC Research catalog of market research reports and place direct orders.
  • Subscribe to any of BCC Research’s many industry newsletters.
  • Read announcements of recently published reports and newly launched newsletters.
  • Register for its well-known conferences.
  • Request additional information on any BCC research product.
  • Take advantage of special offers.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature.  This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature.  The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

REPORT TOC

Pricing on the website is provided for single users and 2-5 users licenses only. Please contact us at (+1)781-489-7301 or send an email to help@bccresearch.com to purchase multi-user licenses.
  Title/Chapter Name Pages Price
Global Markets for Drug-Device Combinations 252 $6650
Chapter- 1: INTRODUCTION - Complimentary 4 $0
  Show Details
Chapter- 2: EXECUTIVE SUMMARY 4 $250
  Show Details
Chapter- 3: CURRENT STATUS OF THE DRUG DEVICE COMBINATION INDUSTRY 9 $356
  Show Details
Chapter- 4: REGULATORY PROCESS AND ISSUES 6 $238
  Show Details
Chapter- 5: NANOTECH COMBINATION PRODUCTS 17 $673
  Show Details
Chapter- 6: DRUG-ELUTING CORONARY STENTS 14 $554
  Show Details
Chapter- 7: PHOTODYNAMIC THERAPIES 12 $475
  Show Details
Chapter- 8: ANTIMICROBIALS AND OTHER MEDICAL DEVICE COATINGS 7 $277
  Show Details
Chapter- 9: ANTIMICROBIAL CATHETERS 10 $396
  Show Details
Chapter- 10: DRUG-ELUTING BEADS 12 $475
  Show Details
Chapter- 11: BONE CEMENTS INCLUDING ANTIBIOTIC 6 $238
  Show Details
Chapter- 12: BONE GRAFT SUBSTITUTES 32 $1267
  Show Details
Chapter- 13: WOUND CARE PRODUCTS INCLUDING BIOLOGICAL DRESSINGS 15 $594
  Show Details
Chapter- 14: DRUG-DEVICE COMBINATION PRODUCTS FOR OCCULAR APPLICATIONS 7 $277
  Show Details
Chapter- 15: IMPLANTABLES AS DRUG-DEVICE COMBINATIONS 5 $198
  Show Details
Chapter- 16: RELATED DRUG-DEVICE COMBINATIONS OF RELEVANCE 12 $475
  Show Details
Chapter- 17: PATENT ANALYSIS 30 $1188
  Show Details
Chapter- 18: INDUSTRY STRUCTURE AND COMPANY PROFILES 44 $1742
  Show Details
Chapter- 19: APPENDIX 1: RECENT FDA APPROVALS OF DEVICES, INCLUDING COMBINATION PRODUCTS 5 $198
  Show Details
Chapter- 20: APPENDIX 2: GLOSSARY OF RELEVANT TERMINOLOGY 1 $40
  Show Details
 
  List of Tables
  List of Figures
 
  • Purchase Report
  • Download Table of Contents
  • Contact Us